BioSpace News Archive

Synlogic, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to labafenogene marselecobac for the treatment of phenylketonuria.

AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs further agreement with the IEO, one of the most renowned comprehensive cancer centers in Europe.

Quest Diagnostics, the leader in diagnostic information services, announced the launch of its first consumer-initiated genetic test, now exclusively available through the company’s consumer health business at questhealth.com.

Sampled today announced that it has been named a Certified Service Provider for PacBio, a leading developer of high-quality, highly accurate sequencing solutions, equipping Sampled to deliver the highest quality advanced sequencing technology services on PacBio’s technology.

BrainsWay Ltd. today announced the expanded market penetration of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in India.

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has dosed the first participant in the Phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).

SYBLEU INC. is preparing to begin advancing small molecule drug therapies for animal and human health.

QurAlis Corporation today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for QRL-201 for the potential treatment of ALS.

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reveals new findings from data to be presented at the annual Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands. AAIC is the largest medical meeting focused on Alzheimer’s Disease (AD).

Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ has been chosen by Synlogic, (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options.